University of Virginia
Cardiovascular Disease fellowship · Charlottesville, VA · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Virginia's research in cardiovascular disease, which the program shares with other departments and affiliated hospitals.
About University of Virginiainstitution-wide cardiovascular disease research
Cardiovascular Disease publications from University of Virginia and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
141
works per year
26th of 78 cardiovascular disease fellowship programs
+15.7%
2-year growth
38th of 78 cardiovascular disease fellowship programs
25.8%
in top 10% of field (works before 2025)
32nd of 74 cardiovascular disease fellowship programs
45.2%
cited above world average
29th of 74 cardiovascular disease fellowship programs
Works per year · * 2026 so far
Cardiology and Cardiovascular Medicine · 704
Cardiovascular Disease research topics at University of Virginia
Papers in the window; each links to the list on OpenAlex.
- Cardiac Valve Diseases and Treatments 131
- Heart Failure Treatment and Management 57
- Cardiomyopathy and Myosin Studies 49
- Cardiovascular Function and Risk Factors 35
- Renin-Angiotensin System Studies 33
- Cardiac Fibrosis and Remodeling 32
- Atrial Fibrillation Management and Outcomes 31
- Heart Rate Variability and Autonomic Control 25
Most cited at University of Virginia since 2024
All cardiovascular disease papers there on OpenAlex
- EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic OrganMartin Czerny et al. · The Annals of Thoracic Surgery · 2024 · PubMed · cited 361
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart FailureChristopher M. Kramer et al. · Journal of the American College of Cardiology · 2024 · PubMed · cited 197
- Pericardial DiseasesAllan L. Klein et al. · JACC. Cardiovascular imaging · 2024 · PubMed · cited 181
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialBarry A. Borlaug et al. · Nature Medicine · 2024 · PubMed · cited 161
- Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of AmericaMichelle Weisfelner Bloom et al. · Journal of Cardiac Failure · 2024 · PubMed · cited 120
- Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathyRafik Tadros et al. · Nature Genetics · 2025 · PubMed · cited 72
- Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic CardiomyopathyAhmad Masri et al. · Journal of the American College of Cardiology · 2024 · PubMed · cited 67
- Structural Heart Imaging Using 3-Dimensional Intracardiac EchocardiographyGilbert H.L. Tang et al. · JACC. Cardiovascular imaging · 2024 · PubMed · cited 65
- Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri et al. · Journal of Cardiac Failure · 2024 · PubMed · cited 64
- SCMR expert consensus statement for cardiovascular magnetic resonance of patients with a cardiac implantable electronic deviceDaniel J. Kim et al. · Journal of Cardiovascular Magnetic Resonance · 2024 · PubMed · cited 62